

FORM 51-102F3

Material Change Report

Item 1. Name and Address of Company

Blackhawk Growth Corp. (the “Company”)
Suite 2200, 885 West Georgia Street
Vancouver, B.C., V6C 3E8

Item 2. Date of Material Change

News Release dated December 22, 2020.

Item 3. News Release

The Company disseminated a news release concerning the material change described herein on December 22, 2020 and subsequently filed a copy on SEDAR at www.sedar.com.

Item 4. Summary of Material Change

Blackhawk provides update on Covid Rapid Test Kit Operations.

Item 5. Full Description of Material Change

Vancouver, British Columbia – December 22, 2020 – Blackhawk Growth Corp. (CSE:BLR) (CNSX:BLR.CN) (Frankfurt:0JJ) (US OTC:BLRZF) (the “Company“), is pleased to announce that it continues to sell the SARS-CoV-2 IgG / IgM Rapid Test Kits and the ExProbe SARS-CoV-2 Testing Kits. Blackhawk is still awaiting Health Canada interim order to allow for sales of the kits within Canada, as outlined below, but continues to grow the sale of the kits in jurisdictions outside of Canada.

Since entering definitive distribution agreements (the “Distribution Agreement”) to distribute certain diagnostic products, including the ExProbe SARS-CoV-2 Testing Kit and a SARS-CoV-2 IgG/IgM Rapid Test Kit (collectively, the “Test Kits”) used in the detection associated with COVID-19, Blackhawk has sold over 5,000 Test Kits with gross sales revenue of approximately \$75,000USD. Sales of the Test Kits have been focused on the United States market. Blackhawk expects the sales to continue to grow as the Covid-19 virus numbers of infections and required testing reaches critical levels in numerous States in the US. With the success of the Blackhawk sales efforts, the distribution agreement has been mutually extended.

In addition, Blackhawk continues to provide the required information to Health Canada in the hopes that it receives the approval to provide the Test Kits throughout Canada.

The Health Canada Interim Order (“IO”) for its SARS-CoV-2 IgG / IgM Rapid Test Kit application was submitted on November 4th, 2020 and the Company received a “*request for additional information*” letter from Health Canada on November 12th. In order to provide a

full & comprehensive response to Health Canada materials requested by Health Canada were completed and submitted on December 13th, 2020.

The Health Canada Interim Order (“IO”) for its ExProbe SARS-CoV-2 Testing Kit was completed and submitted November 13th 2020 and is currently listed as “Under Review”. Both the ExProbe SARS-CoV-2 and SARS-CoV-2 IgG / IgM Rapid Test Kit are currently USA FDA EUA Authorized and carry a CE mark overseas.

Blackhawk makes no representations or provides any guarantees on Health Canada’s review timelines.

For further information please contact:

Frederick Pels, Chief Executive Officer

(403)-991-7737

fred@blackhawkgrowth.com

.Item 6. Reliance on subsection 7.1(2) or (3) of National Instrument 51-102

Not applicable

Item 7. Omitted Information

Not applicable

Item 8. Executive Officer

The following senior officer of the Company is knowledgeable about the material change disclosed in this report.

Frederick Pels
Chief Executive Officer
Telephone: 403-991-7737

Item 9. Date of Report

December 22, 2020